![Vera Franzén](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Vera Franzén
Nessuna posizione attualmente
Profilo
Vera Franzén worked as a Director of Regulatory Affairs at SentoClone AB.
Precedenti posizioni note di Vera Franzén
Società | Posizione | Fine |
---|---|---|
SentoClone AB
![]() SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Consigliere Generale | 31/12/2012 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
SentoClone AB
![]() SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Commercial Services |
- Borsa valori
- Insiders
- Vera Franzén